Pricing Log in Create free account

CG Oncology, Inc. (CGON) vs Mirum Pharmaceuticals, Inc. (MIRM)

CG Oncology, Inc. and Mirum Pharmaceuticals, Inc. are both Biotechnology companies. CG Oncology, Inc. and Mirum Pharmaceuticals, Inc. are of similar size ($6.1B and $5.7B). CG Oncology, Inc. grew revenue faster over the last twelve months: 840.8% against 42.2%. Mirum Pharmaceuticals, Inc. has the higher net margin (−134.8% vs −3,602.7%) and the higher return on invested capital (−184.7% vs −4,111.6%). Across the 16 metrics below, Mirum Pharmaceuticals, Inc. leads on 10 and CG Oncology, Inc. on 6.

Valuation

Metric CGON MIRM Biotechnology median
P/E n/m n/m 10.26
P/S 918.54 9.18 9.18
P/B 5.56 n/m 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 755.35 9.72 8.98
Earnings yield (4.15%) (16.19%) (34.89%)
Free cash flow yield (3.14%) (5.01%) (24.52%)

Profitability

Metric CGON MIRM Biotechnology median
Gross margin (85.20%) 81.72% 65.16%
Operating margin (4,056.18%) (133.62%) 0.00%
Net margin (3,602.68%) (134.75%) 0.00%
Free cash flow margin (2,879.62%) (46.04%) 0.00%
Return on equity (26.41%) (760.01%) (50.12%)
Return on assets (25.11%) (99.78%) (45.60%)
Return on invested capital (4,111.64%) (184.65%) 0.00%

Growth

Metric CGON MIRM Biotechnology median
Revenue growth (TTM) 840.79% 42.18% 6.26%
EPS growth (last fiscal year) (47.52%) 74.59% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CGON MIRM Biotechnology median
Debt to equity 0.00 (13.50) 0.00
Current ratio 22.22 2.07 4.89
Net debt to EBITDA 3.88 (19.11) 1.01

Dividend

Metric CGON MIRM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CGON MIRM Biotechnology median
Market cap 5.74b 6.11b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack